Blunted Dopamine Release as a Biomarker for Vulnerability for Substance Use Disorders - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue Biological Psychiatry Année : 2014

Blunted Dopamine Release as a Biomarker for Vulnerability for Substance Use Disorders

Résumé

Imaging of the striatal dopamine system continues to dominate studies using positron emission tomography (PET) in substance use disorders (SUD). A key reason for this is the stability of the findings: most studies imaging the dopamine D2 family of receptors (D2R) and stimulant-induced dopamine release show blunting of striatal dopamine transmission in subjects with addiction. This phenotype is seen across SUDs, including cocaine, nicotine, alcohol, opiate, and methamphetamine. Reduced binding at the D2R persists independently of many clinical factors, and this effect is maintained following days to months of abstinence.

Dates et versions

hal-02636569 , version 1 (27-05-2020)

Identifiants

Citer

Pierre Trifilieff, Diana Martinez. Blunted Dopamine Release as a Biomarker for Vulnerability for Substance Use Disorders. Biological Psychiatry, 2014, 76 (1), pp.4-5. ⟨10.1016/j.biopsych.2014.04.017⟩. ⟨hal-02636569⟩
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More